DIAGNOSTIC VALUE OF ENDOTHELIN 1 AND ENDOTHELI GROWTH FACTOR AND VALUE FOR DETERMINING THE THERAPEUTIC EFFECTIVENESS OF L-ARGININE ASPARTANE IN ISCHEMIC DISEASE.
Keywords:
VEGF; ET-1; myocardial infarction; coronary heart disease; L-arginine aspartate; EZVD.Abstract
Ischemic heart disease is the most common cause of death in the world. According to WHO, 740 million people die every year in the world, of which 13.2% die due to coronary heart disease.
References
Elsky V.N., Vatutin N.T., Kalinkina N.V., Salakhova A.M. (2008) The role of endothelial dysfunction in the genesis of cardiovascular diseases. Journal. AMS of Ukraine, 14(1): 51–62.
Abbate A., Toldo S., Marchetti C., Kron J., Van Tassell B.W., Dinarello C.A. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ. Res. 2020;126:1260–1280. doi: 10.1161/CIRCRESAHA.120.315937. [PMC free article]
Abhinand C.S., Raju R., Soumya S.J., Arya P.S., Sudhakaran P.R. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J. Cell Commun. Signal. 2016;10:347–354. doi: 10.1007/s12079-016-0352-8. [PMC free article]
Abukar Y., May C.N., Ramchandra R. Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure. Am. J. Physiol. Integr. Comp. Physiol. 2016;310:R94–R99. doi: 10.1152/ajpregu.00205.2015.
Afzal M.R., Samanta A., Shah Z.I., Jeevanantham V., Abdel-Latif A., Zuba-Surma E.K., Dawn B. Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials. Circ. Res. 2015;117:558–575. doi: 10.1161/CIRCRESAHA.114.304792. [PMC free article]
Albrecht-Schgoer K., Schgoer W., Holfeld J., Theurl M., Wiedemann D., Steger C., Gupta R., Semsroth S., Fischer-Colbrie R., Beer A.G.E., et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2012;126:2491–2501. doi: 10.1161/CIRCULATIONAHA.111.076950. [PMC free article]
Alexander S.P., Fabbro D., Kelly E., Marrion N., Peters J.A., Benson H.E., Faccenda E., Pawson A.J., Sharman J.L., Southan C., et al. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br. J. Pharmacol. 2015;172:5979–6023. doi: 10.1111/bph.13353. [PMC freearticle]
Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., Ruschitzka F., Lüscher T.F. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347–354. doi: 10.1016/S0140-6736(04)16723-8.
Ancey C., Corbi P., Froger J., Delwail A., Wijdenes J., Gascan H., Potreau D., Lecron J.-C. Secretion of IL-6, IL-11 and lif by human cardiomyocytes in primary culture. Cytokine. 2002;18:199–205. doi: 10.1006/cyto.2002.1033.
Anisimov A., Tvorogov D., Alitalo A., Leppänen V.-M., An Y., Han E.C., Orsenigo F., Gaál E.I., Holopainen T., Koh Y.J., et al. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127:424–434. doi: 10.1161/CIRCULATIONAHA.112.127472.
Antithrombotic Trialists’ (ATT) Collaboration. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet Lond. Engl. 2009;373:1849–1860. doi: 10.1016/S0140-6736(09)60503-1. [PMC free article]
Aoyagi T., Matsui T. The Cardiomyocyte as a Source of Cytokines in Cardiac Injury. J. Cell Sci. Ther. 2011;2012 doi: 10.4172/2157-7013.S5-003. [PMC free article]
Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732. doi: 10.1038/348730a0.
Arrillaga-Romany I., Norden A.D. Antiangiogenic therapies for glioblastoma. CNS Oncol. 2014;3:349–358. doi: 10.2217/cns.14.31. [PMC free article]
Arsic N., Zentilin L., Zacchigna S., Santoro D., Stanta G., Salvi A., Sinagra G., Giacca M. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol. Ther. J. Am. Soc. Gene Ther. 2003;7:450–459. doi: 10.1016/S1525-0016(03)00034-0.
Asahara T., Chen D., Tsurumi Y., Kearney M., Rossow S., Passeri J., Symes J.F., Isner J.M. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation. 1996;94:3291–3302. doi: 10.1161/01.CIR.94.12.3291.
Azimi-Nezhad M. Vascular endothelial growth factor from embryonic status to cardiovascular pathology. Rep. Biochem. Mol. Biol. 2014;2:59–69. [PMC free article] [PubMed] [Google Scholar]
Badimon L., Suades R., Crespo J., Padro T., Chiva-Blanch G. Diet, microparticles and atherothrombosis. Front. Biosci. LandmarkEd. 2018;23:432–457. doi: 10.2741/4598.
Banquet S., Gomez E., Nicol L., Edwards-Lévy F., Henry J.-P., Cao R., Schapman D., Dautreaux B., Lallemand F., Bauer F., et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation. 2011;124:1059–1069. doi: 10.1161/CIRCULATIONAHA.110.010264.
Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336–3343. doi: 10.1182/blood.V87.8.3336.bloodjournal8783336.
Barton M., Yanagisawa M. Endothelin: 30 years from discovery to therapy. Hypertension. 2019;74:1232–1265. doi: 10.1161/HYPERTENSIONAHA.119.12105.
Beck H., Plate K.H. Angiogenesis after cerebral ischemia. ActaNeuropathol. (Berl.) 2009;117:481–496. doi: 10.1007/s00401-009-0483-6.
Bohm F., Jensen J., Svane B., Settergren M., Pernow J. Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can. J. Physiol. Pharmacol. 2008;86:745–751. doi: 10.1139/Y08-081.
Bohm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc. Res. 2007;76:8–18. doi: 10.1016/j.cardiores.2007.06.004.
Borgers M., Voipio-Pulkki L.-M., Izumo S. Apoptosis. Cardiovasc. Res. 2000;45: 525–527. doi: 10.1016/S0008-6363(99)00404-6.
Borgeson D.D., Grantham J.A., Williamson E.E., Luchner A., Redfield M.M., Opgenorth T.J., Burnett J.C. Chronic Oral Endothelin Type A Receptor Antagonism in Experimental Heart Failure. Hypertension. 1998;31:766–770. doi: 10.1161/01.HYP.31.3.766.
Camaré C., Pucelle M., Nègre-Salvayre A., Salvayre R. Angiogenesis in the atherosclerotic plaque. Redox Biol. 2017;12:18–34. doi: 10.1016/j.redox.2017.01.007. [PMC free article]
Campia U., Tesauro M., Di Daniele N., Cardillo C. The vascular endothelin system in obesity and type 2 diabetes: Pathophysiology and therapeutic implications. LifeSci. 2014;118:149–155. doi: 10.1016/j.lfs.2014.02.028.
